ПРОТИВОВИРУСНАЯ ТЕРАПИЯ У ТРУДНЫХ ПАЦИЕНТОВ С HCV-ИНФЕКЦИЕЙ

Скачать статью в PDF
Номер журнала: 
7
Год издания: 
2017

Т. Симанкова, А. Балашова, О. Аришева, кандидат медицинских наук, И. Гармаш, кандидат медицинских наук, В. Моисеев, академик РАН, профессор Российский университет дружбы народов, Москва E-mail: nastasya.balashova@yandex.ru

Изучены эффективность и безопасность ингибитора протеазы NS3/4A симепревира у трудных больных с HCV-инфекцией.
Ключевые слова: 
гастроэнтерология
цирроз
гепатит С
симепревир
ингибиторы протеаз
Для цитирования
Симанкова Т., Балашова А., Аришева О., Гармаш И. ПРОТИВОВИРУСНАЯ ТЕРАПИЯ У ТРУДНЫХ ПАЦИЕНТОВ С HCV-ИНФЕКЦИЕЙ . Врач, 2017; (7): 35-38

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Perz J., Armstrong G., Farrington L. et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide // J. Hepatol. – 2006; 45 (4): 529–38.
  2. Лопаткина Т.Н. Хронический гепатит С: внепеченочные проявления, особенности клинического течения, диагностика // Вирусные гепатиты: инф. бюлл. – 2000; 2 (3): 5–6.
  3. World Health Organization. Global Alert and Response: Hepatitis C. http:/www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index1.html
  4. Deuffic-Burban S., Babany G., Lonjon-Domanec I. et al. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France // Hepatology. – 2009; 50: 1351–9.
  5. Drenth J. HCV Treatment – No More Room for Interferonologists? // N. Engl. J. Med. – 2013; 368: 1931–2.
  6. Kuntzen T., Timm J., Berical A. et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naпve patients // Hepatology. – 2008; 48 (6): 1769–78.
  7. McHutchison J., Everson G., Gordon S. et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection // N. Engl. J. Med. – 2009; 360: 1827–38.
  8. Romano K., Ali A., Schiffer C. Avoiding drug resistance against HCV NS3/4A protease inhibitors. [abstract 17] // Antiviral Therapy. – 2010; 15 (Suppl. 2): A1–A189.
  9. FDA Approves Incivek (telaprevir) for People with Hepatitis C / Vertex Press Releases, 2011.
  10. Alessio Agherno. 24-th Conference of Asian Pacific Association for the Study of the Liver (APASL) / Istanbul, Turkey, 2015.
  11. Heim M. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end // Nat. Rev. Immunol. – 2013; 13: 535–42.
  12. Jacobson I., McHutchision J., Dusheiko G. et al. Telaprevir for previousiy untreated chronic hepatitis C virus infection // N. Engl. J. Med. – 2011; 364 (25): 2405–16.
  13. Poordad F., McCone J. Jr., Bacon B. et al. Boceprevir for untreated chronic HCV genotip 1 infection // N. Engl. J. Med. – 2011; 364 (13): 1195–206.
  14. You D., Pockros P. Simeprevir for the treatment of chronic hepatitis C // Expert Opin. Pharmacother. – 2013; 14 (18): 2581–9.
  15. Jacobson I. SVR results of a once-daily regimen of simeprevir (TMC-438) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Program and abstracts of American Association for the Study of Liver Diseases The Liver Meeting®. 2013. Abstract LB-3.
  16. Forns X., Lawitz E., Zeuzem S. et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial // Gastroenterology. – 2014; 146: 1669–79.
  17. Jacobson I., Dore G., Foster G. et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial // Lancet. – 2014; 384: 403–13.
  18. Manns M., Marcellin P., Poordad F. et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial // Lancet. – 2014; 384: 414–26.
  19. Reddy K., Zeuzem S., Zoulim F. et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial // Lancet Infect. Dis. – 2015; 15: 27–35.
  20. EASL Recommendations on Treatment of Hepatitis C 2015 // J. Hepatol. – 2015; 63: 199–236.
  21. Ledinghen V., Vergniol J. Transient elastography (FibroScan) // Gastrœntérol. Clin. Bio. – 2008; 32: 58–67.
  22. D’Ambrosio R., Aghemo A., Fraquelli M. et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response // J. Hepatol. – 2013; 59: 251–6.
  23. Vergniol J., Foucher J., Terrebonne E. et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C // Gastroenterology. – 2011; 140: 1970–9.
  24. Lontok E., Harrington P., Howe A. et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary // Hepatology. – 2015; 62 (5): 1623–32. doi: 10.1002/hep.27934. Epub 2015 Jul 30.
  25. Lenz O., Verbinnen T., Fevery B. et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies // J. Hepatol. – 2015; 62 (5): 1008–14. doi: 10.1016/j.jhep.2014.11.032. Epub 2014 Nov. 28.